Abstract
Active monitoring of health outcomes after COVID-19 vaccination provides early detection of rare outcomes post-licensure.
Objective To evaluate health outcomes following bivalent COVID-19 Pfizer-BioNTech (BNT162b2) and Moderna (mRNA-1273.222) vaccination among individuals 6 months and older in the United States.
Design Monthly monitoring of health outcomes from August 2022 to July 2023 in four administrative claims databases. Descriptive analyses monitored vaccine uptake, outcome counts and coadministration of bivalent COVID-19 and influenza vaccines. Sequential analyses tested for elevated risk of each outcome in a prespecified post-vaccination risk interval, or a period of hypothesized elevation based on clinical guidance, compared to a historical baseline.
Participants and Exposures Persons 6 months and older who received a bivalent COVID-19 BNT162b2 or mRNA-1273.222 vaccine during the study period, with continuous enrollment in a medical insurance plan from the start of an outcome-specific clean interval to the COVID-19 vaccination date. Vaccines were identified using product-specific codes from medical coding systems.
Health Outcomes Twenty outcomes were monitored in BNT162b2 vaccine recipients 6 months-4 years, and mRNA-1273.222 vaccine recipients 6 months-5 years. Twenty-one outcomes were monitored in BNT162b2 vaccine recipients 5-17 years and mRNA-1273.222 vaccine recipients 6-17 years. Eighteen outcomes were monitored in persons 18 years and older for both mRNA vaccines.
Results Overall, 13.9 million individuals 6 months and older received a single bivalent COVID-19 mRNA vaccine. The statistical threshold for a signal was met for two outcomes in one database: anaphylaxis following bivalent BNT162b2 and mRNA-1273.222 vaccines in persons 18-64 years and myocarditis/pericarditis following bivalent BNT162b2 vaccines in individuals 18-35 years. There were no signals identified in young children.
Conclusions Results were consistent with prior observations from published studies on COVID-19 vaccine safety. This study supports the safety profile of bivalent COVID-19 mRNA vaccines and the conclusion that the benefits of vaccination outweigh the risks.
Competing Interest Statement
Co-authors from U.S. Food and Drug Administration and Acumen LLC declared no conflicts of interests. The following authors reported a conflict of interest: Kandace L. Amend, 1 John D. Seeger, 1 Jennifer Song,1 Robin Clifford, 1 Cheryl N. McMahill-Walraven,2 Djeneba Audrey Djibo,2 Jonathan P. DeShazo,2 Eugenio Abente,2 Daniel C. Bleacher,3 Alex Secora,4 Nandini Selvam.4 1Employee of Optum, with reported stock or stock options in UnitedHealth Group. 2Employee of CVS Health. 3Employee of Elevance Health Incorporated. 4Employee of IQVIA.
Funding Statement
The US Food and Drug Administration provided funding for this study and contributed as follows: led the design of the study, interpretation of the results, writing of the manuscript, decision to submit, and made contributions to the coordination of data collection and analysis of the data.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Patricia C. Lloyd (patricia.lloyd{at}fda.hhs.gov), Elizabeth R. Smith (esmith{at}acumenllc.com), Joann F. Gruber (joann.gruber{at}fda.hhs.gov), Michelle Ondari (mondari{at}acumenllc.com), Hui Lee Wong (huilee.wong{at}fda.hhs.gov), Mao Hu (mhu{at}acumenllc.com), Tainya C. Clarke (tainya.clarke{at}fda.hhs.gov), Rowan McEvoy (rmcevoy{at}acumenllc.com), Kandace L. Amend (kandace.amend{at}optum.com), Daniel C. Beachler (daniel.beachler{at}carelon.com), Cheryl N McMahill-Walraven (cheryl.walraven{at}cvshealth.com), John D. Seeger (john.seeger{at}optum.com), Alex Secora (alex.secora{at}iqvia.com), Djeneba Audrey Djibo (audrey.djibo{at}cvshealth.com), Jennifer Song (jennifer.song{at}optum.com), Nandini Selvam (nandini.selvam{at}iqvia.com), Jonathan P. DeShazo (jonathan.deshazo{at}cvshealth.com), Robin Clifford (robin.clifford{at}optum.com), Eugenio Abente (abentee{at}aetna.com), Yoganand Chillarige (ychillarige{at}acumenllc.com), Richard A. Forshee (richard.forshee{at}fda.hhs.gov), Steven A. Anderson (steven.anderson{at}fda.hhs.gov), Azadeh Shoaibi (azadeh.shoaibi{at}nih.gov).
Data Availability
The data used in the present study is confidential and is not available for reference.
